(Q33600272)

English

A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

enzyme replacement therapy

0 references

Gaucher's disease

1 reference

based on heuristic

inferred from title

3

object named as

Neal Weinreb

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Gregory M Pastores

1

object named as

Gregory M Pastores

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

author name string

Barry Rosenbloom

2

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Ozlem Goker-Alpan

4

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Gregory Grabowski

5

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Gabriel M Cohn

6

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

David Zahrieh

7

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

language of work or name

0 references

publication date

21 November 2013

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Genetics in Medicine

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

359-366

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018500

21 June 2018

Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018500

21 June 2018

Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018500

21 June 2018

An evidence-based review of the potential benefits of taliglucerase alfa in the treatment of patients with Gaucher disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018500

21 June 2018

Velaglucerase alfa: a new option for Gaucher disease treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018500

21 June 2018

Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018500

21 June 2018

Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018500

21 June 2018

Gaucher disease: clinical profile and therapeutic developments

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018500

21 June 2018

Phase 1/2 and extension study of velaglucerase alfa replacement therapy in adults with type 1 Gaucher disease: 48-month experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018500

21 June 2018

Recombinant glucocerebrosidase (imiglucerase) as a therapy for Gaucher disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018500

21 June 2018

Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018500

21 June 2018

The long-term international safety experience of imiglucerase therapy for Gaucher disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018500

21 June 2018

A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1

1 reference

https://pubmed.ncbi.nlm.nih.gov/24263462

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration

1 reference

https://pubmed.ncbi.nlm.nih.gov/24263462

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources

1 reference

https://pubmed.ncbi.nlm.nih.gov/24263462

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: early Access Program results from Jerusalem

1 reference

https://pubmed.ncbi.nlm.nih.gov/24263462

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/GIM.2013.154

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33600272&oldid=2246680842"